ABC Baseline Medications and Therapies in Efficacy and Impact of Botulinum Toxin A versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence

Assessment of baseline medications and therapies, CSV
Study Description
Urinary incontinence is a condition that markedly impacts quality of life. Conservative first line treatments for urge incontinence combined with other overactive bladder (OAB) symptoms include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and are often not sustained for various reasons. Thus, the objective of the Anticholinergic versus Botox Comparison Study (ABC) was to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence (UUI). Oral anticholinergic therapy and Botox A® by injection were associated with similar reductions in the frequency of daily episodes of UUI. The group receiving Botox A® was less likely to have dry mouth and more likely to have complete resolution of UUI but had higher rates of transient urinary retention and urinary tract infections. Participants were females at least 21 years of age with urge predominant urinary incontinence based on a self-reported diary who desired treatment for urge urinary incontinence.

基线用药与治疗方案评估（CSV格式）
研究描述
尿失禁（Urinary incontinence）是一种显著影响生活质量的疾病。针对合并其他膀胱过度活动症（OAB）症状的急迫性尿失禁，一线保守治疗方案包括行为疗法、盆底肌训练联合或不联合生物反馈，或使用抗胆碱能药物（Anticholinergic medications）。此类治疗方案往往无法实现完全控尿，且受多种因素影响常难以维持长期疗效。因此，本抗胆碱能药物与肉毒素对比研究（Anticholinergic versus Botox Comparison Study, ABC）旨在明确单次膀胱内注射A型肉毒杆菌毒素（Botox A®）是否较标准化口服抗胆碱能药物方案更能有效减少急迫性尿失禁（UUI）的每日发作频次。
研究结果显示，口服抗胆碱能药物治疗与Botox A®注射治疗，均可使每日急迫性尿失禁发作频次得到相似程度的降低。接受Botox A®注射的受试者口干不良反应发生率更低，且更易实现急迫性尿失禁的完全缓解，但一过性尿潴留与尿路感染的发生率更高。本研究的受试者为年龄≥21岁、经自我排尿日记确诊为急迫性为主型尿失禁且因急迫性尿失禁寻求治疗的女性。